title: Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.
abstract: Vaccinia CC-36 murine colon oncolysate (VCO) prepared with interleukin-2-gene encoded recombinant vaccinia virus (IL-2VCO) was used in the treatment of a syngeneic murine colon adenocarcinoma (CC-36) hepatic metastasis to test the beneficial effect of the interleukin-2-gene encoded vaccinia virus over a control recombinant vaccinia virus in producing a vaccinia oncolysate tumor cell vaccine. Results suggest that the IL-2VCO treatment significantly reduced the hepatic tumor burden in comparison with the controls that received either IL-2-gene-encoded recombinant vaccinia virus or a plain recombinant vaccinia virus or vaccinia oncolysate prepared with the plain recombinant virus. The survival of mice treated with IL-2VCO was also improved in comparison with mice treated with other preparations. The induction of a cytolytic T lymphocyte response was examined to elucidate the mechanism of the induction of antitumor responses in IL-2VCO-treated mice. Fresh peripheral blood lymphocytes (PBL) isolated from IL-2VCO-treated mice showed a higher cytolytic activity against CC-36 tumor cell target when compared to PBL from the mice of other treatment groups, suggesting that the IL-2VCO induced an antitumor cytolytic T lymphocyte response. These results suggest that a vaccinia oncolysate, prepared with recombinant vaccinia virus encoding an immunomodulating cytokine gene will enhance antitumor responses in the host.
authors.affiliation: Department of Surgery Research Laboratory, St. Vincent's Hospital and Medical Center, New York, NY 10011.
authors.forename: M
authors.initials: M
authors.lastname: Sivanandham
authors.forename: S D
authors.initials: SD
authors.lastname: Scoggin
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
authors.forename: M K
authors.initials: MK
authors.lastname: Wallack
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology*; D000818:Animals; D003110:Colonic Neoplasms / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D016233:Immunotherapy, Active; D007376:Interleukin-2 / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000556:secondary / Q000628:therapy*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014616:Vaccinia virus / Q000235:genetics*
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins